Taf + Emtricitabine + Rilpivirine Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: (TAF) – 25 mg + Emtricitabine – 200 mg + Rilpivirine – 25 mg
Reference Brands: Odefsey(US & EU)
Category: Anti Viral
Odefsey is a once-daily HIV-1 treatment combining TAF, Emtricitabine, and Rilpivirine. FDA and EMA approved, it offers improved kidney and bone safety compared to TDF-based regimens and must be taken with food. TAF + Emtricitabine + Rilpivirine is available in Tablet and strengths such as (TAF) – 25 mg + Emtricitabine – 200 mg + Rilpivirine – 25 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, TAF + Emtricitabine + Rilpivirine is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
TAF + Emtricitabine + Rilpivirine can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Odefsey is a once-daily, fixed-dose combination tablet containing Tenofovir Alafenamide (TAF) 25 mg, Emtricitabine 200 mg, and Rilpivirine 25 mg, used for the treatment of HIV-1 infection in virologically suppressed patients or treatment-naïve individuals without resistance to its components. Approved by the FDA and EMA, Odefsey is a TAF-based alternative to older TDF regimens like Complera/Eviplera, offering improved renal and bone safety. It is indicated for adults and adolescents (≥12 years and ≥35 kg) and must be taken with a meal. Odefsey simplifies therapy by combining three potent agents into a single-tablet regimen.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Tenofovir alafenamide + emtricitabine + rilpivirine is used for the treatment of HIV-1 infection in adults who are virologically suppressed. It helps maintain viral suppression and supports long-term HIV management as a complete once-daily regimen.
It is made from the active ingredients tenofovir alafenamide (TAF), emtricitabine, and rilpivirine. TAF and emtricitabine are nucleoside reverse transcriptase inhibitors, while rilpivirine is a non-nucleoside reverse transcriptase inhibitor.
The main trade name is Odefsey in the USA, EU, and UK.
Odefsey is manufactured by Gilead Sciences in collaboration with Janssen.
The generic name is tenofovir alafenamide + emtricitabine + rilpivirine.
The primary brand name is Odefsey.
It is manufactured by Gilead Sciences in the USA and EU, along with authorized global production partners.
Related Products
Maraviroc
Strength:
150 mg, 300 mg, 20 mg
Form: Tablets / Oral solution
Reference Brands: Selzentry (USA), Celsentri (EU)
View Details
Raltegravir
Strength:
100mg, 400 mg, 600mg
Form: Tablets
Reference Brands: Isentress (USA/EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
